This commentary summarises recent updates to diabetes management guidelines regarding the use of glucagon-like peptide 1 receptor agonists such as dulaglutide, both as a second-line agent and as a first-line injectable agent in type 2 diabetes. It also provides practical guidance on the use of dulaglutide as an alternative to basal insulin or in combination with insulin by examining the AWARD (Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes) studies. |
The AWARD studies demonstrate that dulaglutide provides effective glucose lowering together with sustained weight loss and a low incidence of hypoglycaemia when used as the first injectable option and when used in combination with titrated basal insulin or prandial insulin. |
The broad range of patients enrolled in the AWARD studies reflect the heterogeneity of the general population of patients with type 2 diabetes, and demonstrate that dulaglutide is a valid treatment option across a wide range of patient characteristics, including different levels of hyperglycaemia, glycaemic patterns, prior oral antidiabetic therapies, age and duration of diabetes, and presence of comorbidities. |
Most patients enrolled in AWARD-9 reported that the standard dulaglutide injection device used in the study and in clinical practice was “easy” or “very easy”, and 90% were satisfied with the overall injection experience. |
Introduction
Guideline Recommendations for GLP-1RAs in T2D
Early Use of GLP-1RAs
GLP-1RAs and Insulin
Dulaglutide and Insulin in the AWARD Studies
Study arms | Additional glycaemic therapy | T2D patient population enrolled | Dulaglutide 1.5 mg baseline patient characteristics | Key findings | |
---|---|---|---|---|---|
AWARD-2 [7] | Dulaglutide 0.75 mg QW Dulaglutide 1.5 mg QW Insulin glargine daily | Metformin + glimepiride | HbA1c 7–11% [53–97 mmol/mol] on 1–3 oral antidiabetic agents (n = 810) | Age 56 ± 10 years Duration of diabetes 9 ± 6 years HbA1c 8.2 ± 1.0% [65.5 ± 10.8 mmol/mol] Weight (BMI) 85 ± 18 kg (31 ± 5) | Greater HbA1c reduction and weight loss with dulaglutide 1.5 mg QW than insulin glargine once daily, both in combination with metformin + SU At 52 weeks, change in HbA1c was − 1.08 ± 0.06% vs − 0.63 ± 0.06% (− 11.8 ± 0.7 mmol/mol vs − 6.9 ± 0.7 mmol/mol), respectively; p < 0.001 for superiority |
AWARD-4 [9] | Dulaglutide 0.75 mg QW Dulaglutide 1.5 mg QW Insulin glargine daily (bedtime) | Metformin (optional) Insulin lispro | HbA1c 7–11% [53–97 mmol/mol] on stable dose(s) of any type of insulin (± oral antidiabetic agent) | Age 58.9 ± 9.6 years Duration of diabetes 12.8 ± 7.2 years HbA1c 8.46 ± 1.08% [68.95 ± 11.8 mmol/mol] Weight (BMI) 91.0 ± 18.2 kg (32.0 ± 5.1) | Greater HbA1c reduction and weight loss with dulaglutide 1.5 mg QW than insulin glargine once daily, both in combination with insulin lispro At 26 weeks, change in HbA1c was − 1.64% [95% CI − 1.78 to − 1.50%] vs − 1.41% [− 1.55 to − 1.27%] (− 17.93 mmol/mol [− 19.44 to − 16.42] vs − 15.41 mmol/mol [− 16.92 to − 13.90]), respectively; p = 0.005 |
AWARD-7 [10] | Dulaglutide 0.75 mg QW Dulaglutide 1.5 mg QW Insulin glargine daily (bedtime) | Metformin (optional) Insulin lispro | Moderate-to-severe CKD with HbA1c 7–10.5% [53–91.3 mmol/mol] on insulin (± oral antidiabetic agent) and maximum tolerated ACEi or ARB | Age 64.7 ± 8.8 years Duration of diabetes 17.6 ± 8.7 years HbA1c 8.6 ± 0.9% [70.5 ± 9.3a mmol/mol] Weight (BMI) 88.1 ± 16 kg (32.1 ± 4.8) | In patients with moderate-to-severe CKD, dulaglutide 1.5 mg QW provided similar reductions in HbA1c to insulin glargine, with a reduced decline in eGFR and overall favourable safety profile At 26 weeks, change in HbA1c was − 1.2 ± 0.1% vs − 1.1 ± 0.1% (− 13.0 ± 1.4 mmol/mol vs − 12.4 ± 1.3 mmol/mol), respectively, p ≤ 0.0001 for non-inferiority |
AWARD-9 [11] | Dulaglutide 1.5 mg QW Placebo | Metformin (optional) Insulin glargine (titrated) | HbA1c 7–10.5% [53–91.3 mmol/mol] on a stable dose of insulin glargine ± metformin (n = 300) | Age 60.2 ± 9.5 years Duration of diabetes 13.0 ± 7.5 years HbA1c 8.4 ± 0.9% [68 ± 9.8 mmol/mol] Weight (BMI) 93.3 ± 17.5 kg (32.8 ± 4.9) | Dulaglutide 1.5 mg added to titrated basal insulin reduced HbA1c and decreased body weight in a placebo-controlled trial At 28 weeks, change in HbA1c was − 1.44 ± 0.09% with dulaglutide + glargine vs − 0.67 ± 0.09% with placebo + glargine (− 15.74 ± 0.98 mmol/mol vs − 7.32 ± 0.98 mmol/mol), p < 0.001 |
Dulaglutide vs Basal Insulin as a First Injectable Option (AWARD-2) [7]
Dulaglutide vs Basal Insulin, Both in Combination with Insulin Lispro (AWARD-4) [9]
Dulaglutide in Patients with Moderate-to-Severe Chronic Kidney Disease (AWARD-7) [10]
Dulaglutide Added to Titrated Basal Insulin (AWARD-9) [11]
Dulaglutide Safety and Patient Considerations
Avoiding Therapeutic Inertia
Key Practice Points
-
As the first injectable option (as an alternative to basal insulin)
-
In combination with insulin lispro (as an alternative to a basal-bolus insulin regimen)
-
In combination with titrated basal insulin (as an add-on therapy to optimised basal insulin)
-
In patients with CKD
-
Glycaemic patterns (high or low fasting blood glucose and post-prandial glucose) [8]